Dr. Martens (LON:DOCS) Stock Price Down 11.6% – Time to Sell?

Dr. Martens plc (LON:DOCS) shares traded down 11.6% during mid-day trading on Tuesday . The company traded as low as GBX 65 and last traded at GBX 66.90. Approximately 9,032,986 shares were traded during trading, an increase of 342% from the average session volume of 2,043,681 shares. The stock had previously closed at GBX 75.65.

Key Headlines Impacting Dr. Martens

Here are the key news stories impacting Dr. Martens this week:

• Positive Sentiment: Berenberg Bank reaffirmed a “buy” rating on DOCS, which supports investor confidence in the brand and long-term growth potential. Broker Rating
• Negative Sentiment: Dr. Martens projected flat revenue for 2026 while saying it will scale back discounts — a move that should help margins but signals limited top-line growth near term, which is weighing on the share price. Revenue Guidance Article

Analyst Ratings Changes

Several equities research analysts have recently issued reports on DOCS shares. Peel Hunt restated a “buy” rating on shares of Dr. Martens in a report on Thursday, November 20th. Berenberg Bank reiterated a “buy” rating on shares of Dr. Martens in a research note on Tuesday. Two analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Dr. Martens has a consensus rating of “Moderate Buy” and an average price target of GBX 6,000.

Dr. Martens Stock Performance

The stock has a market capitalization of £646.63 million, a PE ratio of 39.35, a P/E/G ratio of 6.40 and a beta of 0.11. The company has a debt-to-equity ratio of 127.27, a quick ratio of 1.13 and a current ratio of 2.85. The firm has a 50 day moving average of GBX 76.53 and a 200-day moving average of GBX 83.47.

Dr. Martens (LON:DOCS) last posted its earnings results on Thursday, November 20th. The company reported GBX (0.90) earnings per share (EPS) for the quarter. Dr. Martens had a net margin of 7.89% and a return on equity of 18.91%. Research analysts forecast that Dr. Martens plc will post 2.5809394 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Robert Hanson bought 96,000 shares of Dr. Martens stock in a transaction dated Friday, December 5th. The shares were bought at an average price of GBX 79 per share, for a total transaction of £75,840. Insiders have acquired a total of 97,130 shares of company stock worth $7,673,816 in the last 90 days. 2.79% of the stock is owned by insiders.

Dr. Martens Company Profile

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.